<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124496</url>
  </required_header>
  <id_info>
    <org_study_id>20204146</org_study_id>
    <nct_id>NCT05124496</nct_id>
  </id_info>
  <brief_title>Validation of HyperDetector for SARS-CoV-2</brief_title>
  <official_title>Validation of the HyperDetector Digital Solution Screening Assay for Rapid Screening for Potential SARS-CoV-2 (COVID-19) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HyperSpectral APD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HyperSpectral APD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the HyperDetector as a method to rapidly screen SARS-CoV-2&#xD;
&#xD;
      To determine the sensitivity and specificity of the screening assay performed on oral swab&#xD;
      and saliva specimens, compared to a validated RT-PCR COVID-19 method using nasal or&#xD;
      nasopharyngeal swabs and to separately collected nasal swabs, oral swabs, oral rinse and&#xD;
      saliva samples.&#xD;
&#xD;
      To determine the best workflow for using such an assay to reflex suspicious/positive samples&#xD;
      to a validated RT-PCR COVID-19 assay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Collected sufficient samples for analysis&#xD;
  </why_stopped>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>By 12/30/2022</time_frame>
    <description>To determine the sensitivity of the screening assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>By 12/30/2022</time_frame>
    <description>To determine the specificity of the screening assay</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>SARS-COV2 Infection</condition>
  <arm_group>
    <arm_group_label>Comparison to Rt-PCR</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Screening Device</intervention_name>
    <description>Screening device comparing Rt-PCR positive and negative results to HyperDetector results</description>
    <arm_group_label>Comparison to Rt-PCR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals obtaining Rt-PCR test&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects at COVID-19 testing site for Rt-PCR test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minors under the age of 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Stack</last_name>
    <role>Study Director</role>
    <affiliation>HyperSpectral APD, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HyperSpectral APD, LLC</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

